Price Chart

Executive Summary

Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior therapy. The Phase 3 RASolute 302 trial showed a 60% reduction in death risk (HR 0.40) and median OS of 13.2 months vs 6.7 months for chemotherapy. This is the first approved targeted RAS inhibitor for pancreatic cancer, a major commercial opportunity for RVMD given the high unmet need and large patient population (~55,000 annual US diagnoses).

Key Facts

• FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy
• Phase 3 RASolute 302 trial showed 60% reduction in risk of death (HR 0.40; p<0.0001) vs chemotherapy
• Median overall survival 13.2 months with RASONQUE vs 6.7 months with chemotherapy
• Median progression-free survival 7.2 months vs 3.6 months (HR 0.49; p<0.0001)
• First approved targeted RAS(ON) multi-selective inhibitor for pancreatic cancer
• Once-daily oral tablet now available by prescription in the US with (ON)Path patient support program
• Approval does not require companion diagnostic test; covers patients with or without identified RAS mutation
• Breakthrough Therapy Designation and Orphan Drug Designation granted by FDA
• EMA phased review ongoing; Orphan Medicinal Product designation for pancreatic cancer in EU

Financial Impact

First-in-class RAS inhibitor for ~55,000 annual US PDAC diagnoses with 80% metastatic at diagnosis; 5-year survival ~3% in metastatic setting; no prior targeted therapy existed; pricing not disclosed but represents transformative commercial opportunity for $45B market cap company

Risk Factors

• Competition from other RAS inhibitors in development (e.g., Amgen's sotorasib, Mirati's adagrasib, and other RAS multi-selective programs)
• Safety profile includes dermatologic toxicity (86%), stomatitis (57%), diarrhea (63%), and rare but serious GI perforation (0.9%) and ILD/pneumonitis (2.4%)
• Commercial adoption may be slower than expected if physicians are cautious about new targeted therapy in a difficult-to-treat population
• Pricing and reimbursement uncertainty; patient access programs may limit near-term revenue
• Dependence on single product for revenue; pipeline diversification still in clinical stages

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status